Nevertheless, several pre-clinical studies have shown the promising anti-proliferative potential of SMAP treatment, for example in T-cell acute lymphoblastic leukemia, castration-resistant prostate cancer, KRAS mutant lung adenocarcinoma, and tyrosine kinase inhibitor (TKI)-resistant lung adenocarcinoma (161–164). This evidence concerns the gene KRAS and lung adenocarcinoma.